Just three years ago, Circassia was riding high, raising £200 million ($285 million) from its initial public offering (IPO), making it the most successful European biotech stock launch ever.

Analyst James Orsborne of Stifel Nicolaus assigned a Buy rating on Circassia Pharmaceuticals (NIOX – Research Report), with a price target of ...

UK biotech Circassia has had two key decisions go in its favour with FDA, as the company continues with its efforts to rebuild its business after a series of disastrous allergy drug trial failures.

Circassia Pharmaceuticals ( (GB:NIOX)) has shared an update. Niox Group PLC, a UK-based company, has reported a change in major holdings due to Danske Bank A/S crossing a voting rights threshold.

A global leader in technology used to track maritime vessels has returned to profit and should see earnings surge a ...

The ban was introduced in Dagestan, Ingushetia, Kabardino-Balkaria, Karachai-Circassia, North Ossetia, Chechnya, Donetsk and Lugansk People’s Republics, Zaporozhye and Kherson Regions MOSCOW ...

Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Request A Quote Download PDF Copy Request A Quote Download ...

This quality stock's smart pivot into consumer services is more than offsetting slowing demand fo ...